Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697541 | 0.88 | BRD4 (0.53) | BRD4GRIN1GRIN2B | |
| SCHEMBL20461438 | 0.88 | BRD4 (0.60) | BRD4CYP1A2CYP2C9CYP2C19GRIN1 | |
| SCHEMBL16697167 | 0.88 | BRD4 (0.59) | BRD4 | |
| SCHEMBL16696743 | 0.87 | BRD4 (0.54) | BRD4 | |
| SCHEMBL16697748 | 0.87 | BRD4 (0.60) | BRD4 | |
| SCHEMBL29914074 | 0.87 | BRD4 (0.60) | BRD4 | |
| SCHEMBL18670415 | 0.85 | BRD4 (0.55) | BRD4 | |
| SCHEMBL16696974 | 0.85 | BRD4 (0.60) | BRD4CYP2C9GRIN1GRIN2B | |
| SCHEMBL16697160 | 0.85 | BRD4 (0.52) | BRD4 | |
| SCHEMBL20461543 | 0.84 | BRD4 (0.58) | BRD4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353179-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Plexxikon Inc. (US) | 2018-08-01 | — | — | EP | claimed |
| WO-2017053243-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-03-30 | — | — | WO | claimed |
| US-20170081326-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2017-03-23 | — | — | US | claimed |
| US-12116365-B2 | Heterocyclic compounds and uses thereof | Opna Bio SA (CH) | 2024-10-15 | — | — | US | disclosed |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2022-11-10 | — | — | US | disclosed |
| EP-4071149-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Immuno Oncology, SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| EP-3353179-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2970265-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3353179-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Plexxikon Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718847-B2 | Heterocyclic compounds and uses thereof | PLEXXIKON INC. (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017053243-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PLEXXIKON INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | CYP11B2, CYP11B1, UGT2B7 | BRD4 1363/4885CYP1A2 18/4885CYP2C9 10/4885 |
| US-20150133400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885CYP1A2 18/4885CYP2C9 10/4885 |
| US-20170081326-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | BRD4 1363/4885CYP1A2 18/4885CYP2C9 10/4885 |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | BRD4 1363/4885CYP1A2 18/4885CYP2C9 10/4885 |
| US-20170320899-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, CYP2C19 | BRD4 1365/4885CYP1A2 18/4885CYP2C9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.